Will Belviq revive the obesity treatment market?
Belviq, the new obesity drug approved by the FDA surprisingly in 13 years, was adopted by Ildong Pharmaceutical and started to be sold in the domestic market. Known as ‘Reductil overcoming the cardiovascular side effect,’ Belviq is expected to become a catalyst of the entire market growth as fill...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
